<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024942</url>
  </required_header>
  <id_info>
    <org_study_id>ID 3965</org_study_id>
    <nct_id>NCT05024942</nct_id>
  </id_info>
  <brief_title>LUS in Aortic Stenosis Patients Undergoing TAVR</brief_title>
  <official_title>Lung Ultrasound in Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Francesca Graziani, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stefano Cangemi, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Introduction and aims:&#xD;
&#xD;
           Transcatheter aortic valve replacement (TAVR) is the gold standard for the treatment of&#xD;
           elderly patients with severe aortic valve stenosis (AS). AS causes left ventricular&#xD;
           remodeling as well as left atrial enlargement, pulmonary artery and right ventricular&#xD;
           changes, these changes, and whether they are reversible (reverse remodeling) are major&#xD;
           determinants of outcome after TAVR. Heart Failure (HF) is the most frequent cause of&#xD;
           cardiac re-hospitalization after TAVR. Most HF exacerbations are related to a&#xD;
           progressive rise in cardiac filling pressures that precipitates pulmonary congestion and&#xD;
           symptomatic decompensation. Traditionally, pulmonary congestion has been assessed by&#xD;
           physical examination and chest radiography but clinical signs and symptoms of congestion&#xD;
           are poor surrogates for ventricular filling pressures and are not reliable predictors of&#xD;
           imminent hospitalization. Recently, lung ultrasonography (LUS) has been identified as a&#xD;
           sensitive and semi-quantitative tool for the assessment of pulmonary congestion in HF.&#xD;
           The technique is based on the detection of vertical echogenic artifacts arising from the&#xD;
           pleural line, named &quot;B-lines&quot;. The number of B-lines is associated with increased risk&#xD;
           of adverse events during hospitalization and after hospital discharge. CLUSTER-HF Trial&#xD;
           demonstrated that the routine incorporation of LUS during clinical follow-up of patients&#xD;
           with recent acute decompensated HF without a surgically correctable cause, was&#xD;
           associated with a risk reduction of adverse HF events, mainly urgent HF visits.&#xD;
&#xD;
           Thus, LUS could represent a promising tool to detect pulmonary congestion related to AS.&#xD;
           To date, there are no studies on the role of LUS in the context of AS and TAVR.&#xD;
&#xD;
           The study hypothesis is that in patients with higher number of B-lines before-TAVR and&#xD;
           after TAVR, the rate of adverse events during follow-up is higher.&#xD;
&#xD;
        2. Study design:&#xD;
&#xD;
           This is a single center prospective study carried out at Fondazione Policlinico Gemelli&#xD;
           IRCCS, Roma and involving patients with severe aortic stenosis submitted to TAVR&#xD;
           treatment. The expected recruitment period is approximately one year For patients&#xD;
           fulfilling inclusion/exclusion criteria, all data about clinical status leading to TAVR,&#xD;
           exams and any specific documentation during hospitalization will be collected.&#xD;
&#xD;
        3. Number of patients:&#xD;
&#xD;
           For the primary end-point, a sample-size of 91 is computed using the one-sample&#xD;
           chi-square test and assuming a proportion of LUS-evaluated pulmonary congested patients&#xD;
           before TAVR of 50% and a proportion of 35% of LUS-evaluated pulmonary congested patients&#xD;
           after TAVR. To accommodate for possible missing investigations, sample size will be&#xD;
           increased to 105 patients.&#xD;
&#xD;
           The secondary end-point is the association between pre-TAVR and post-TAVR B-lines and&#xD;
           long-term outcomes. Based on previous studies, the investigators know that the incidence&#xD;
           of rehospitalization for heart failure during one-year after TAVR is 14% and that&#xD;
           patients suffering from heart failure without LUS-evaluated pulmonary congestion are at&#xD;
           very low risk of heart failure rehospitalization during follow-up. So, for sample size&#xD;
           calculation of the secondary endpoint, the investigators estimated a cumulative&#xD;
           incidence higher in the LUS- evaluated pulmonary congestion group with more than 16&#xD;
           B-lines on all scanning sites (30% of events during 1-year of follow-up) with a lower&#xD;
           incidence of 8% in the remaining patients. With an HR of 5 favoring patients wit less&#xD;
           than 15 B-Lines on all scanning, and aiming to a 2-sided alpha level of 0.05 and a power&#xD;
           of 80% the investigators estimated 144 patients. To accommodate for possible missing&#xD;
           investigations, sample size will be increased to 150 patients.&#xD;
&#xD;
        4. In-hospital study schedule:&#xD;
&#xD;
           For each patient, the investigators will obtain from our general hospital database the&#xD;
           following clinical data:&#xD;
&#xD;
             -  Demographic and clinical data documentation;&#xD;
&#xD;
             -  Clinical examination: before TAVR, before discharge and when adverse events occur;&#xD;
&#xD;
             -  Blood analysis;&#xD;
&#xD;
             -  TAVR procedural characteristics and complications.&#xD;
&#xD;
        5. Instrumental diagnostic exams (Echocardiography and lung ultrasound):&#xD;
&#xD;
           Each patient will be evaluated before and after TAVR with a comprehensive echocardiogram&#xD;
           and LUS for the evaluation of the pulmonary congestion. All the evaluations will be&#xD;
           performed the day before TAVR and after TAVR.&#xD;
&#xD;
           In consideration of the operator's dependence on ultrasound methods to reduce the error&#xD;
           rate, all examinations will be performed by qualified personnel.&#xD;
&#xD;
        6. Clinical follow up assessment:&#xD;
&#xD;
      Clinical follow up information will be obtained from: visits, review of the patient's&#xD;
      hospital record, personal communication with the patient's physician and review of the&#xD;
      patient's chart, a telephone interview with the patient conducted by trained medical&#xD;
      personnel The following information will be recorded: clinical status assessment, adverse&#xD;
      event assessment, record cardiac medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change of LUS-evaluated pulmonary congestion in patients with severe aortic stenosis undergoing TAVR</measure>
    <time_frame>pre-intervention (baseline) and after the intervention within 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to evaluate the possible prognostic role of LUS-evaluated pulmonary congestion at 12 months follow-up.</measure>
    <time_frame>One year after hospital discharge.</time_frame>
    <description>The main adverse events considered in the secondary end-point are: death from cardiovascular cause, hospitalization for HF and urgent medical visits for worsening dyspnea in the 12 months following discharge</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <condition>Lung Ultrasound</condition>
  <condition>Severe Aortic Valve Stenosis</condition>
  <condition>Pulmonary Congestion</condition>
  <arm_group>
    <arm_group_label>Severe aortic stenosis patients undergoing TAVR</arm_group_label>
    <description>Severe aortic stenosis patients undergoing TAVR will be stratified according to LUS evaluated pulmonary congestion before and after TAVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transfemoral TAVR (Transcatheter aortic valve replacement)</intervention_name>
    <description>Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.</description>
    <arm_group_label>Severe aortic stenosis patients undergoing TAVR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing TAVR for severe aortic stenosis could participate in the study and&#xD;
        therefore, be evaluated according to the selection criteria defined in the protocol.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  severe aortic stenosis,&#xD;
&#xD;
          -  life expectancy &gt;1 year,&#xD;
&#xD;
          -  patient candidate to percutaneous transfemoral aortic valve implantation after formal&#xD;
             indication of our &quot;Heart Team&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinical history of lung cancer or lung surgery, fibrothorax and pneumothorax,&#xD;
             pulmonary fibrosis,&#xD;
&#xD;
          -  patients undergoing urgent aortic valvuloplasty,&#xD;
&#xD;
          -  patients admitted for cardiogenic shock,&#xD;
&#xD;
          -  recent (within 1 month) pneumonia or ARDS (Acute Respiratory Distress Syndrome),&#xD;
&#xD;
          -  lack of will to participate,&#xD;
&#xD;
          -  more than moderate aortic regurgitation,&#xD;
&#xD;
          -  valve-in-valve procedures,&#xD;
&#xD;
          -  transapical and transaortic TAVR.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico A. Gemelli. Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Burzotta, MD, PhD</last_name>
      <phone>349-429-5290</phone>
      <phone_ext>+39</phone_ext>
      <email>francesco.burzotta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francesco Burzotta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP; SURTAVI Investigators. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017 Apr 6;376(14):1321-1331. doi: 10.1056/NEJMoa1700456. Epub 2017 Mar 17.</citation>
    <PMID>28304219</PMID>
  </reference>
  <reference>
    <citation>Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932. Epub 2020 Dec 17. Erratum in: Circulation. 2021 Feb 2;143(5):e228. Circulation. 2021 Mar 9;143(10):e784.</citation>
    <PMID>33332149</PMID>
  </reference>
  <reference>
    <citation>Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchétché D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16.</citation>
    <PMID>30883053</PMID>
  </reference>
  <reference>
    <citation>Treibel TA, Badiani S, Lloyd G, Moon JC. Multimodality Imaging Markers of Adverse Myocardial Remodeling in Aortic Stenosis. JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 1):1532-1548. doi: 10.1016/j.jcmg.2019.02.034. Review.</citation>
    <PMID>31395243</PMID>
  </reference>
  <reference>
    <citation>Lindman BR, Stewart WJ, Pibarot P, Hahn RT, Otto CM, Xu K, Devereux RB, Weissman NJ, Enriquez-Sarano M, Szeto WY, Makkar R, Miller DC, Lerakis S, Kapadia S, Bowers B, Greason KL, McAndrew TC, Lei Y, Leon MB, Douglas PS. Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. JACC Cardiovasc Interv. 2014 Jun;7(6):662-73. doi: 10.1016/j.jcin.2014.02.011.</citation>
    <PMID>24947722</PMID>
  </reference>
  <reference>
    <citation>Généreux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson LG, Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto WY, Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, Kodali SK, Smith CR, Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J. 2017 Dec 1;38(45):3351-3358. doi: 10.1093/eurheartj/ehx381.</citation>
    <PMID>29020232</PMID>
  </reference>
  <reference>
    <citation>Vemulapalli S, Dai D, Hammill BG, Baron SJ, Cohen DJ, Mack MJ, Holmes DR Jr. Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement: The STS/ACC TVT Registry. J Am Coll Cardiol. 2019 Mar 19;73(10):1135-1146. doi: 10.1016/j.jacc.2018.12.049.</citation>
    <PMID>30871697</PMID>
  </reference>
  <reference>
    <citation>Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G; European Society of Cardiology; European Society of Intensive Care Medicine. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010 May;12(5):423-33. doi: 10.1093/eurjhf/hfq045. Epub 2010 Mar 30. Review.</citation>
    <PMID>20354029</PMID>
  </reference>
  <reference>
    <citation>Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008 Sep 30;118(14):1433-41. doi: 10.1161/CIRCULATIONAHA.108.783910. Epub 2008 Sep 15.</citation>
    <PMID>18794390</PMID>
  </reference>
  <reference>
    <citation>Rivas-Lasarte M, Maestro A, Fernández-Martínez J, López-López L, Solé-González E, Vives-Borrás M, Montero S, Mesado N, Pirla MJ, Mirabet S, Fluvià P, Brossa V, Sionis A, Roig E, Cinca J, Álvarez-García J. Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure. ESC Heart Fail. 2020 Oct;7(5):2621-2628. doi: 10.1002/ehf2.12842. Epub 2020 Jul 7.</citation>
    <PMID>32633473</PMID>
  </reference>
  <reference>
    <citation>Platz E, Campbell RT, Claggett B, Lewis EF, Groarke JD, Docherty KF, Lee MMY, Merz AA, Silverman M, Swamy V, Lindner M, Rivero J, Solomon SD, McMurray JJV. Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. JACC Heart Fail. 2019 Oct;7(10):849-858. doi: 10.1016/j.jchf.2019.07.008.</citation>
    <PMID>31582107</PMID>
  </reference>
  <reference>
    <citation>Picano E, Scali MC, Ciampi Q, Lichtenstein D. Lung Ultrasound for the Cardiologist. JACC Cardiovasc Imaging. 2018 Nov;11(11):1692-1705. doi: 10.1016/j.jcmg.2018.06.023. Review.</citation>
    <PMID>30409330</PMID>
  </reference>
  <reference>
    <citation>Araiza-Garaygordobil D, Gopar-Nieto R, Martinez-Amezcua P, Cabello-López A, Alanis-Estrada G, Luna-Herbert A, González-Pacheco H, Paredes-Paucar CP, Sierra-Lara MD, Briseño-De la Cruz JL, Rodriguez-Zanella H, Martinez-Rios MA, Arias-Mendoza A. A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study). Am Heart J. 2020 Sep;227:31-39. doi: 10.1016/j.ahj.2020.06.003. Epub 2020 Jun 15.</citation>
    <PMID>32668323</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Francesco Burzotta</investigator_full_name>
    <investigator_title>MD, PhD, interventional cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

